


# Efficient Synthesis of Chiral Trisubstituted 1,2-Allenyl Ketones by Catalytic Asymmetric Conjugate Addition of Malonic Esters to Enynes

Qian Yao, Yuting Liao, Lili Lin, Xiaobin Lin, Jie Ji, Xiaohua Liu,\* and Xiaoming Feng\*

**Abstract:** An *N,N'*-dioxide/scandium(III) complex catalyzed, highly efficient conjugate addition of malonic esters to enynes is described. A range of trisubstituted 1,2-allenyl ketones were obtained in high yields (up to 99%) with good d.r. (up to 95/5) and excellent ee values (97%–99%). Moreover, the products could be easily transformed into chiral furan and 5-hydroxypyrazoline derivatives, both of which are important skeletons of many biologically active compounds and pharmacologicals.

Chiral allenes are valuable compounds for their importance in organic synthesis and pharmaceuticals.<sup>[1,2]</sup> Over the past two decades, substantial efforts have been devoted to their asymmetric synthesis.<sup>[3]</sup> Early successful examples were limited to the use of stoichiometric amounts of chiral auxiliaries/promoters or enantioenriched substrates.<sup>[4]</sup> Until now, some ingenious methods for catalytic asymmetric synthesis of chiral allenes have been reported. They include the isomerization of 3-alkynes,<sup>[5]</sup> kinetic resolution of racemic allenes,<sup>[6]</sup> β-hydride elimination of enol triflates,<sup>[7]</sup> desymmetrization of *meso*-allenes<sup>[8]</sup> or alkynes,<sup>[9]</sup> rearrangements of alkynes,<sup>[10]</sup> C–H insertion of α-diazoesters into 1-alkynes,<sup>[11]</sup> functionalization of racemic allenes,<sup>[12]</sup> and addition to enynes.<sup>[13]</sup> Among them, addition to enynes is a simple but very efficient route to obtain chiral allenes. For instance, Hayashi has pioneered a metal-catalyzed enyne addition for synthesis of chiral allenes (Scheme 1a).<sup>[13a–c]</sup> Subsequently, Tang has provided an intramolecular enyne addition for the highly diastereo- and enantioselective synthesis of bromoallenes in the presence of chiral ureas (Scheme 1b).<sup>[13d]</sup> Zhang has developed an intermolecular enyne addition in the assistance of chiral thioureas (Scheme 1c).<sup>[13e]</sup> Although a series of 2,3-allenoates were obtained with up to 98% ee



**Scheme 1.** Comparison of previous catalytic asymmetric enyne addition for synthesis of chiral allenes with current work.

value, there was only one example containing the axial and carbon center chirality with 4:1 d.r. Furthermore, the reaction also gave the byproduct alkynoate as a result of direct conjugate addition (Scheme 1c). Zhang has also reported two racemic enyne addition to construct contiguous axial and carbon center,<sup>[14]</sup> but the catalytic asymmetric manner is still unrealized. In short, the highly diastereoselective and enantioselective construction of continuous axial and carbon center chirality by intermolecular enyne addition is a challenge. Stimulated by the successful application of our unique catalysts in conjugate addition,<sup>[15]</sup> herein, we report a highly efficient conjugate addition of malonic esters to enynes catalyzed by an *N,N'*-dioxide/scandium(III) complex, affording a range of trisubstituted 1,2-allenyl ketones. It should be mentioned that the direct conjugate addition product alkynoates **4** were not detected during the reaction course (Scheme 1).


Our investigation began with the addition of diethyl malonate (**2b**) to enyne (**1a**) as the model reaction to optimize the reaction conditions. Initially, chiral ligands were evaluated (Table 1, entries 1–3). The results showed that by complexing with Sc(OTf)<sub>3</sub>, L-proline-derived L-PrEt<sub>2</sub>Me, L-ramipril-derived L-RaEt<sub>2</sub>Me, and L-pipeolic acid-derived L-PiEt<sub>2</sub>Me, all of the complexes could promote the reaction

[\*] Q. Yao, Y. T. Liao, Dr. L. L. Lin, X. B. Lin, J. Ji, Prof. Dr. X. H. Liu, Prof. Dr. X. M. Feng  
Key Laboratory of Green Chemistry and Technology  
Ministry of Education, College of Chemistry  
Sichuan University  
Chengdu 610064 (China)  
E-mail: liuxh@scu.edu.cn  
xmfeng@scu.edu.cn

Prof. Dr. X. M. Feng  
Collaborative Innovation Center of  
Chemical Science and Engineering (Tianjin) (China)

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.201509455>.

© 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

**Table 1:** Optimization of the reaction conditions.<sup>[a]</sup>


Entry	L	Base	Yield [%] <sup>[b]</sup>	ee [%] <sup>[c]</sup>	d.r. <sup>[d]</sup>
1	L-PrEt <sub>2</sub> Me	DMAP	98	76:76	67:33
2	L-PrEt <sub>2</sub> Me	DMAP	98	99:99	64:36
3	L-PiEt <sub>2</sub> Me	DMAP	98	99:99	68:32
4	L-PiEt <sub>2</sub> Me	Na <sub>2</sub> CO <sub>3</sub>	93	98:99	84:16
5	L-PiEt <sub>2</sub> Me	iPr <sub>2</sub> EtN	89	95:95	86:14
6	L-PiEt <sub>2</sub> Me	nBu <sub>3</sub> N	88	98:98	88:12
7 <sup>[e]</sup>	L-PiEt <sub>2</sub> Me	nBu <sub>3</sub> N	85	99:99	92:8
8 <sup>[f]</sup>	L-PiEt <sub>2</sub> Me	nBu <sub>3</sub> N	66	99:99	93:7

[a] Unless otherwise noted, reactions were carried out with L (10 mol %), Sc(OTf)<sub>3</sub> (10 mol %), base (10 mol %), **1a** (0.2 mmol), **2b** (0.8 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (0.8 mL) at 30°C for 24 h. [b] Yield of isolated product.

[c] Determined by chiral HPLC analysis. [d] Determined by <sup>1</sup>H NMR analysis. [e] Reactions were carried out at 0°C. [f] Reactions were carried out at -5°C.

smoothly in the presence of 4-dimethylaminopyridine (DMAP) at 30°C. However, the diastereoselectivity was low even though the enantioselectivity was moderate to excellent. To improve the diastereoselectivity, other bases were investigated (Table 1, entries 4–6). To our delight, nBu<sub>3</sub>N gave the highest 88:12 d.r. (Table 1, entry 6). Gratifyingly, when the reaction temperature was decreased to 0°C, the diastereoselectivity could be further enhanced to 92:8 (Table 1, entry 7). Unfortunately, the d.r. value could not be improved significantly (93:7) by continuing to decrease the reaction temperature to -5°C (Table 1, entry 8). Thus, the optimized reaction conditions were established as Sc(OTf)<sub>3</sub>/L-PiEt<sub>2</sub>Me (10 mol %), nBu<sub>3</sub>N (10 mol %), **1a**:**2b** = 1:4 in CH<sub>2</sub>Cl<sub>2</sub> at 0°C.

With the optimized conditions in hand, the reaction scope was next examined. As shown in Table 2, enynes tethering aryl or alkyl substituents (R<sup>1</sup>) on the carbonyl group are suitable substrates, providing the desired trisubstituted 1,2-allenyl ketones in high yields with high d.r. and excellent ee values (Table 2, entries 1–4). Regardless of the electron-withdrawing or electron-donating groups on the 4-position of aromatic rings on the double bond (R<sup>2</sup>), there was little influence on the reaction. The corresponding products were obtained in high yields (88–94 %) with excellent d.r. (92:8–95:5) and ee values (99 %) (Table 2, entries 6–9). When the R<sup>2</sup> group was changed to 2-chlorophenyl, it just gave a moderate yield (77 %) and d.r. (78:22; Table 2, entries 5). Various substituents (R<sup>3</sup>) on the triple bond were also examined. The aryl groups bearing an electron-donating substituent furnished higher diastereoselectivities than electron-withdrawing groups (Table 2, entries 15–17 vs. entries 10–14). The

**Table 2:** Substrate scope for enynes.<sup>[a,b]</sup>

Entry	R <sup>1</sup> /R <sup>2</sup> /R <sup>3</sup>	Yield [%] <sup>[c]</sup>	ee [%] <sup>[d]</sup>	d.r. <sup>[e]</sup>
1	Ph/Ph/Ph	85 ( <b>3 ab</b> )	99	92:8
2	3-MeC <sub>6</sub> H <sub>4</sub> /Ph/Ph	84 ( <b>3 bb</b> )	99	91:9
3 <sup>[f]</sup>	3-ClC <sub>6</sub> H <sub>4</sub> /Ph/Ph	98 ( <b>3 cb</b> )	99	91:9
4	CH <sub>3</sub> /Ph/Ph	92 ( <b>3 db</b> )	98	89:11
5	Ph/2-ClC <sub>6</sub> H <sub>4</sub> /Ph	77 ( <b>3 eb</b> )	97	78:22
6 <sup>[f]</sup>	Ph/4-ClC <sub>6</sub> H <sub>4</sub> /Ph	90 ( <b>3 fb</b> )	99	92:8
7 <sup>[f]</sup>	Ph/4-BrC <sub>6</sub> H <sub>4</sub> /Ph	94 ( <b>3 gb</b> )	99	93:7
8 <sup>[f]</sup>	Ph/4-MeC <sub>6</sub> H <sub>4</sub> /Ph	90 ( <b>3 hb</b> )	99	94:6
9	Ph/4-MeOC <sub>6</sub> H <sub>4</sub> /Ph	88 ( <b>3 ib</b> )	99	95:5
10 <sup>[f]</sup>	Ph/Ph/2-FC <sub>6</sub> H <sub>4</sub>	94 ( <b>3 jb</b> )	99	91:9
11 <sup>[f]</sup>	Ph/Ph/3-FC <sub>6</sub> H <sub>4</sub>	91 ( <b>3 kb</b> )	99	92:8
12	Ph/Ph/4-FC <sub>6</sub> H <sub>4</sub>	90 ( <b>3 lb</b> )	99	88:12
13	Ph/Ph/2-ClC <sub>6</sub> H <sub>4</sub>	93 ( <b>3 mb</b> )	99	89:11
14 <sup>[f]</sup>	Ph/Ph/4-ClC <sub>6</sub> H <sub>4</sub>	96 ( <b>3 nb</b> )	99	89:11
15 <sup>[f]</sup>	Ph/Ph/3-MeC <sub>6</sub> H <sub>4</sub>	75 ( <b>3 ob</b> )	99	94:6
16	Ph/Ph/4-MeC <sub>6</sub> H <sub>4</sub>	91 ( <b>3 pb</b> )	99	93:7
17	Ph/Ph/4-MeOC <sub>6</sub> H <sub>4</sub>	59 ( <b>3 qb</b> )	99	93:7
18 <sup>[f]</sup>	Ph/Ph/3-Thienyl	90 ( <b>3 rb</b> )	97	94:6
19	Ph/Ph/nBu	73 ( <b>3 sb</b> )	99	89:11

[a] Unless otherwise noted, reactions were carried out with L-PiEt<sub>2</sub>Me (10 mol %), Sc(OTf)<sub>3</sub> (10 mol %), nBu<sub>3</sub>N (10 mol %), **1** (0.2 mmol), **2b** (0.8 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (0.8 mL) at 0°C for 24 h. [b] Enyne **1t** (R<sup>1</sup> = OEt, R<sup>2</sup> = H, and R<sup>3</sup> = Ph) was also examined. For results, see the Supporting Information. [c] Yield of isolated product. [d] Determined by chiral HPLC analysis. [e] Determined by <sup>1</sup>H NMR analysis. [f] Reactions were carried out at -5°C.

enyne **1r** containing a 3-thienyl group afforded the desired product **3rb** in 90 % yield with 97 % ee and 94:6 d.r. by decreasing the reaction temperature to -5°C (Table 2, entry 18). The n-butyl-substituted **1s** was also a competent substrate, providing the allene **3sb** with good results (Table 2, entry 19).

Several malonic esters **2** were also tested (Table 3). Although the reactivity and diastereoselectivity markedly

**Table 3:** Substrate scope for malonic esters.<sup>[a]</sup>

1	2	3
<b>3aa:</b> 88% yield <sup>[b]</sup> 89:11 d.r., <sup>[c]</sup> 99% ee <sup>[d]</sup> .	<b>3ac:</b> 82% yield <sup>[b]</sup> 86:14 d.r., <sup>[c]</sup> 98% ee <sup>[d]</sup> .	<b>3ad:</b> 61% yield <sup>[b]</sup> 69:31 d.r., <sup>[c]</sup> 99% ee <sup>[d]</sup> .
		<b>3cd:</b> 78% yield <sup>[b]</sup> 64:36 d.r., <sup>[c]</sup> 98% ee <sup>[d]</sup> . (>99:1 d.r., <sup>[c]</sup> >99% ee <sup>[d]</sup> ).


[a] Reactions were carried out with L-PiEt<sub>2</sub>Me (10 mol %), Sc(OTf)<sub>3</sub> (10 mol %), nBu<sub>3</sub>N (10 mol %), **1** (0.2 mmol), **2** (0.8 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (0.8 mL) at 0°C (for **3aa**) or 30°C (for **3ac**, **3ad**, and **3cd**) for 24 h.

[b] Yield of isolated product. [c] Determined by <sup>1</sup>H NMR analysis.

[d] Determined by chiral HPLC analysis. [e] After recrystallization from CH<sub>2</sub>Cl<sub>2</sub>, the absolute configuration of **3cd** was determined by X-ray crystallography.

decreased with the increased steric hindrance of ester alkyl group ( $R_2$ ), the *ee* values were maintained. To determine the absolute configuration of products, **3cd** was synthesized (Table 3). After recrystallized from  $\text{CH}_2\text{Cl}_2$ , **3cd** with >99:1 d.r. and >99% *ee* could be obtained. The absolute configuration of **3cd** was determined by X-ray crystallography to be (*R,S<sub>a</sub>*).<sup>[16]</sup>


To show the synthetic potential of this strategy, a gram scale synthesis of **3ab** was carried out (Scheme 2a). Under the optimized condition, 3 mmol of **1a** reacted smoothly with 4 equivalents of **2b** to provide 1.27 g **3ab** (91% yield) with



**Scheme 2.** a) Gram-scale version of the reaction. b) Transformation of 1,2-allenyl ketone **3ab**.

91:9 d.r. and 99% *ee*. Furthermore, when treated with 1.2 equiv of **4a** at 30°C, **3ab** could be transformed to the tetrasubstituted 5-hydroxypyrazoline **5a** in 62% yield with 54:46 d.r. (99% *ee* each).<sup>[17]</sup> Importantly, the family of **5a** has been reported to possess antimicrobial,<sup>[18]</sup> anti-PDE<sub>3</sub>,<sup>[19]</sup> anti-inflammatory,<sup>[20]</sup> antimarial,<sup>[21]</sup> hypolipidemic,<sup>[22]</sup> and analgesic<sup>[23]</sup> activities (Scheme 2b). Additionally, **3ab** could also be transformed to trisubstituted furan **5b** under treatment by  $\text{AuCl}_3$  in 79% yield with 99% *ee*,<sup>[24,25]</sup> which are important skeletons for many biologically active compounds and pharmacologicals (Scheme 2b).

To gain insight into the function of  $n\text{Bu}_3\text{N}$  in our system, some control experiments were carried out (Scheme 3). First, when the reaction of **1a** and **2b** was performed in the absence of  $n\text{Bu}_3\text{N}$  (Scheme 3a), it gave a trace amount of **3ab**. This suggested that  $n\text{Bu}_3\text{N}$  served as an effective promoter for the formation of enolate from **2**. Second, when **3ab** (91:9 d.r. and 99% *ee*) was dissolved in  $\text{CH}_2\text{Cl}_2$  and stirred at room temperature for 40 h, there was no influence on its d.r. and *ee* values. In contrast, when  $n\text{Bu}_3\text{N}$  was added to the mixture, the d.r. value rapidly decreased to 62:38 (Scheme 3b). Clearly,  $n\text{Bu}_3\text{N}$  was the cause of the




**Scheme 3.** Control experiments.

reduction in the d.r. value of **3ab**. An additional derivation of the recovered **3ab** (62:38 d.r.) was undertaken, and the produced furan was obtained with 99% *ee*. This demonstrated that the low d.r. was attributed to the partial racemization of axial chirality of the allene (Scheme 3b). In other words,  $n\text{Bu}_3\text{N}$  might not participate in the allenes production, but instead serves as an effective promoter for the formation of enolates from **2** in the catalytic system.

Based on the determination of the absolute configuration of product **3cd**,<sup>[16]</sup> control experiments, and our previous study,<sup>[26]</sup> a possible catalytic cycle with a transition-state model was proposed (Figure 1). First, the *N*-oxides and amide oxygen atoms of L-PiEt<sub>2</sub>Me coordinate to Sc<sup>3+</sup> in a tetradentate manner to form two six-membered chelate rings. Then, enynes **1** attach to Sc<sup>3+</sup> at the favorable equatorial position to give intermediate **T1**. Additionally, the enolates are generated from malonates **2** assisted by  $n\text{Bu}_3\text{N}$ . The *Re* face of enynes **1** are strongly shielded by the nearby benzyl ring. Therefore, the incoming enolates prefers to attack enynes **1** from the *Si* face (**T2**). Finally, the desired products **3** dissociate after a protonation of the favored intermediate **T3**, and the catalyst is regenerated to accomplish one catalytic cycle.

In summary, we have developed an efficient *N,N'*-dioxide/scandium complex catalyst for the intermolecular addition of



**Figure 1.** Proposed catalytic cycle.

malonic esters to enynes. A range of trisubstituted 1,2-allenyl ketones were obtained in good to excellent yields (up to 99 %) with high d.r. (up to 95:5) and excellent *ee* values (up to 99 %). The products could be easily transformed into furan and 5-hydroxypyrazoline derivatives, which are important skeletons in many biologically active compound and pharmacologicals. Moreover, based on the experiments and our previous work, a possible catalytic cycle was proposed.

### Experimental Section

A dry reaction tube was charged with L-PiEt<sub>2</sub>Me (0.02 mmol) and Sc(OTf)<sub>3</sub> (0.02 mmol), enyne **1a** (0.2 mmol) under an N<sub>2</sub> atmosphere, malonic ester **2b** (0.8 mmol), and CH<sub>2</sub>Cl<sub>2</sub> (0.8 mL) were added and the mixture was stirred at 0 °C for 15 min. Then *n*Bu<sub>3</sub>N (0.02 mmol) was added and the mixture was stirred at 0 °C for 24 h. The reaction mixture was purified by column chromatography on silica gel (ethyl acetate/petroleum ether 1:50:1:4) to afford the desired product **3ab** (85 % yield, 99 % *ee*, 92:8 d.r.).

### Acknowledgements

We appreciate the National Natural Science Foundation of China (Nos. 21372162, 21432006, and 21321061) for financial support.

**Keywords:** 1,2-allenyl ketones · 5-hydroxypyrazoline · asymmetric catalysis · enyne addition · furans

**How to cite:** *Angew. Chem. Int. Ed.* **2016**, *55*, 1859–1863  
*Angew. Chem.* **2016**, *128*, 1891–1895

- [1] For recent reviews on allenes in organic synthesis, see: a) S. Ma, *Acc. Chem. Res.* **2003**, *36*, 701; b) S. Ma, *Chem. Rev.* **2005**, *105*, 2829; c) B. J. Cowen, S. J. Miller, *Chem. Soc. Rev.* **2009**, *38*, 3102; d) C. Aubert, L. Fensterbank, P. Garcia, M. Malacria, A. Simonneau, *Chem. Rev.* **2011**, *111*, 1954; e) S. Yu, S. Ma, *Angew. Chem. Int. Ed.* **2012**, *51*, 3074; *Angew. Chem.* **2012**, *124*, 3128; f) J. Ye, S. Ma, *Acc. Chem. Res.* **2014**, *47*, 989.
- [2] A. Hoffmann-Röder, N. Krause, *Angew. Chem. Int. Ed.* **2004**, *43*, 1196; *Angew. Chem.* **2004**, *116*, 1216.
- [3] For recent reviews on asymmetric synthesis of allenes, see: a) M. Ogasawara, *Tetrahedron: Asymmetry* **2009**, *20*, 259; b) R. K. Neff, D. E. Frantz, *ACS Catal.* **2014**, *4*, 519.
- [4] For selected early examples of asymmetric synthesis of allenes using stoichiometric amounts of chiral auxiliaries/promoters or enantioenriched substrates, see: a) Y. Nishibayashi, J. D. Singh, S.-i. Fukuzawa, S. Uemura, *J. Org. Chem.* **1995**, *60*, 4114; b) J. A. Marshall, M. A. Wolf, *J. Org. Chem.* **1996**, *61*, 3238; c) Y. Naruse, H. Watanabe, Y. Ishiyama, T. Yoshida, *J. Org. Chem.* **1997**, *62*, 3862; d) K. Mikami, A. Yoshida, *Angew. Chem. Int. Ed. Engl.* **1997**, *36*, 858; *Angew. Chem.* **1997**, *109*, 892.
- [5] H. Liu, D. Leow, K.-W. Huang, C.-H. Tan, *J. Am. Chem. Soc.* **2009**, *131*, 7212.
- [6] J. Yu, W.-J. Chen, L.-Z. Gong, *Org. Lett.* **2010**, *12*, 4050.
- [7] I. T. Crouch, R. K. Neff, D. E. Frantz, *J. Am. Chem. Soc.* **2013**, *135*, 4970.
- [8] C. Manzuna Sapu, J. E. Bäckvall, J. Deska, *Angew. Chem. Int. Ed.* **2011**, *50*, 9731; *Angew. Chem.* **2011**, *123*, 9905.
- [9] H. Li, D. Müller, L. Guénée, A. Alexakis, *Org. Lett.* **2012**, *14*, 5880.
- [10] a) Z. Li, V. Boyarskikh, J. H. Hansen, J. Autschbach, D. Musaeiv, H. M. L. Davies, *J. Am. Chem. Soc.* **2012**, *134*, 15497; b) Y. Wang, W. Zhang, S. Ma, *J. Am. Chem. Soc.* **2013**, *135*, 11517; c) Y. B. Liu, H. P. Hu, H. F. Zheng, Y. Xia, X. H. Liu, L. L. Lin, X. M. Feng, *Angew. Chem. Int. Ed.* **2014**, *53*, 11579; *Angew. Chem.* **2014**, *126*, 11763.
- [11] Y. Tang, Q. G. Chen, X. H. Liu, G. Wang, L. L. Lin, X. M. Feng, *Angew. Chem. Int. Ed.* **2015**, *54*, 9512; *Angew. Chem.* **2015**, *127*, 9648.
- [12] a) Y. Imada, M. Nishida, K. Kutsuwa, S.-I. Murahashi, T. Naota, *Org. Lett.* **2005**, *7*, 5837; b) A. Boutier, C. Kammerer-Pentier, N. Krause, G. Prestat, G. Poli, *Chem. Eur. J.* **2012**, *18*, 3840; c) T. Hashimoto, K. Sakata, F. Tamakuni, M. J. Dutton, K. Maruoka, *Nat. Chem.* **2013**, *5*, 240; d) B. Wan, S. Ma, *Angew. Chem. Int. Ed.* **2013**, *52*, 441; *Angew. Chem.* **2013**, *125*, 459; e) C. T. Mbafana, S. J. Miller, *J. Am. Chem. Soc.* **2014**, *136*, 3285.
- [13] a) J. W. Han, N. Tokunaga, T. Hayashi, *J. Am. Chem. Soc.* **2001**, *123*, 12915; b) T. Hayashi, N. Tokunaga, K. Inoue, *Org. Lett.* **2004**, *6*, 305; c) T. Nishimura, H. Makino, M. Nagaosa, T. Hayashi, *J. Am. Chem. Soc.* **2010**, *132*, 12865; d) W. Zhang, S. Q. Zheng, N. Liu, J. B. Werness, I. A. Guzei, W. P. Tang, *J. Am. Chem. Soc.* **2010**, *132*, 3664; e) H. Qian, X. Yu, J. Zhang, J. Sun, *J. Am. Chem. Soc.* **2013**, *135*, 18020.
- [14] a) X. Yu, H. Ren, Y. Xiao, J. Zhang, *Chem. Eur. J.* **2008**, *14*, 8481; b) X. Yu, J. Zhang, *Adv. Synth. Catal.* **2011**, *353*, 1265.
- [15] For reviews on chiral N-oxides in asymmetric catalysis, see: a) A. V. Malkov, P. Kočovsky, *Curr. Org. Chem.* **2003**, *7*, 1737; b) G. Chelucci, G. Murineddu, G. A. Pinna, *Tetrahedron: Asymmetry* **2004**, *15*, 1373; c) A. V. Malkov, P. Kočovsky, *Eur. J. Org. Chem.* **2007**, *29*; d) X. M. Feng, X. H. Liu, in *Scandium: Compounds, Productions and Applications* (Ed: V. A. Greene), Nova Science, New York, **2011**, pp. 1–48; e) X. H. Liu, L. L. Lin, X. M. Feng, *Acc. Chem. Res.* **2011**, *44*, 574; f) K. Shen, X. H. Liu, L. L. Lin, X. M. Feng, *Chem. Sci.* **2012**, *3*, 327; g) X. H. Liu, L. L. Lin, X. M. Feng, *Org. Chem. Front.* **2014**, *1*, 298; For recent examples on asymmetric conjugate addition, see: h) Z. Wang, Z. L. Zhang, Q. Yao, X. H. Liu, Y. F. Cai, L. L. Lin, X. M. Feng, *Chem. Eur. J.* **2013**, *19*, 8591; i) Z. Wang, Q. Yao, T. F. Kang, J. H. Feng, X. H. Liu, L. L. Lin, X. M. Feng, *Chem. Commun.* **2014**, *50*, 4918; j) Q. Yao, Z. Wang, Y. H. Zhang, X. H. Liu, L. L. Lin, X. M. Feng, *J. Org. Chem.* **2015**, *80*, 5704.
- [16] CCDC 1044535 (**3cd**).
- [17] S. Guo, J. Wang, D. Guo, X. Zhang, X. Fan, *Tetrahedron* **2012**, *68*, 7768.
- [18] a) Y. Zhao, A. Bacher, B. Illarionov, M. Fischer, G. Georg, Q.-Z. Ye, P. E. Fanwick, S. G. Franzblau, B. Wan, M. Cushman, *J. Org. Chem.* **2009**, *74*, 5297; b) M. S. Karthikyan, B. S. Holla, N. S. Kumari, *Eur. J. Med. Chem.* **2007**, *42*, 30; c) H. G. Bonacorso, A. P. Wentz, R. V. Lourega, C. A. Cechinel, T. S. Moraes, H. S. Coelho, N. Zanatta, M. A. P. Martins, M. Höerner, S. H. Alves, *Fluorine Chem.* **2006**, *127*, 1066.
- [19] K. Y. Kim, H. Lee, S.-E. Yoo, S. H. Kim, N. S. Kang, *Bioorg. Med. Chem. Lett.* **2011**, *21*, 1617.
- [20] a) P. D. Sauzem, P. Machado, M. A. Rubin, G. S. Sant'Anna, H. B. Faber, A. H. de Souza, C. F. Mello, P. Beck, R. A. Burrow, H. G. Bonacorso, N. Zanatta, M. A. P. Martins, *Eur. J. Med. Chem.* **2008**, *43*, 1237; b) F. R. de Souza, M. R. Fighera, T. T. F. Lima, J. de Bastiani, I. B. Barcellos, C. E. Almeida, M. R. Oliveira, H. G. Bonacorso, A. E. Flores, *Pharmacol. Biochem. Behav.* **2001**, *68*, 525.
- [21] W. Cunico, C. A. Cechinel, H. G. Bonacorso, M. A. P. Martins, N. Zanatta, M. V. N. de Souza, I. O. Freitas, R. P. P. Soares, A. U. Krettl, *Bioorg. Med. Chem. Lett.* **2006**, *16*, 649.
- [22] G. A. Idrees, O. M. Aly, G. E.-D. A. A. Abuo-Rahma, M. F. Radwan, *Eur. J. Med. Chem.* **2009**, *44*, 3973.
- [23] a) P. Machado, F. A. Rosa, M. Rossatto, G. S. Sant'Anna, P. D. Sauzem, R. M. Siqueira da Silva, M. A. Rubin, J. Ferreira, H. G. Bonacorso, N. Zanatta, M. A. P. Martins, *ARKIVOC* **2007**, 281; b) P. Machado, P. T. Campos, G. R. Lima, F. A. Rosa, A. F. C.

- Flores, H. G. Bonacorso, N. Zanatta, M. A. P. Martins, *J. Mol. Struct.* **2009**, *917*, 176.
- [24] a) A. S. Dudnik, A. W. Sromek, M. Rubina, J. T. Kim, A. V. Kel'in, V. Gevorgyan, *J. Am. Chem. Soc.* **2008**, *130*, 1440; b) A. S. K. Hashmi, L. Schwarz, J.-H. Choi, T. M. Frost, *Angew. Chem. Int. Ed.* **2000**, *39*, 2285; *Angew. Chem.* **2000**, *112*, 2382.
- [25] a) K. C. Nicolaou, E. J. Sorensen, *Classics in Total Synthesis*, VCH, Weinheim, **1996**; b) A. F. Pozharskii, A. T. Soldatenkov, A. R. Katritzky, in *Heterocycles in Life and Society*, Wiley, Chichester, **1997**; c) H.-K. Lee, K.-F. Chan, C.-W. Hui, H.-K. Yim, X.-W. Wu, H. N. C. Wong, *Pure Appl. Chem.* **2005**, *77*, 139; d) M. Ash, I. Ash, in *Handbook of Flavors and Fragrances*, Synapse Information Resources, New York, **2006**.
- [26] Z. Wang, D. H. Chen, Z. Y. Yang, S. Bai, X. H. Liu, L. L. Lin, X. M. Feng, *Chem. Eur. J.* **2010**, *16*, 10130.

Received: October 9, 2015

Revised: November 10, 2015

Published online: December 22, 2015